Annual Report

The report describes BioInvent's 2021 progress in immuno-oncology, including positive interim BI-1206 data, a SEK 962 million directed share issue, and expansion of its clinical pipeline. It reports 90 people at year-end and links the company's activities to six Agenda 2030 goals. The report also describes environmental controls, limited emissions, waste handling, and a new Code of Conduct.